Clinical Trials

18 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06083454 2026-03-13

Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)

Phase 1 Terminated

1 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05632809 2026-03-11

REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)

39 enrolled

Lung Neoplasms

NCT05696782 2026-03-06

Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

28 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04716946 2026-03-04

Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy

13 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05068232 2026-03-04

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

49 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04602533 2026-02-27

Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)

105 enrolled

Lung Neoplasms

NCT06773910 2026-02-27

TIGOS-LS

250 enrolled

Limited Stage Small Cell Lung Cancer

NCT04892953 2026-02-19

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

51 enrolled

Lung Neoplasms

NCT05403723 2026-02-19

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

Phase 1 Suspended

50 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT07149363 2026-02-17

Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

65 enrolled

Small Cell Lung Carcinoma

NCT04585477 2026-02-10

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05443971 2026-02-06

Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen

Phase 1 Terminated

4 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07339059 2026-01-30

SG and Immunotherapy as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer

35 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT05206812 2026-01-27

Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)

25 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04334759 2026-01-22

DREAM3R

Phase 3 Completed

214 enrolled

Phase 1/2 Active not recruiting

Mesothelioma, Malignant, Mesothelioma

NCT04748419 2026-01-22

Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab

6 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05624996 2026-01-14

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Phase 3 Recruiting

474 enrolled

Lung Neoplasms

NCT03075527 2026-01-08

A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma

Phase 2 Terminated

19 enrolled 12 charts

Phase 1 Active not recruiting

Mesothelioma

NCT03923270 2026-01-08

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

25 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT06124118 2026-01-08

NOVOCURE

Phase 1 Recruiting

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04699838 2026-01-02

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

30 enrolled

Extensive Stage Small Cell Lung Cancer

NCT04224337 2025-12-31

Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma

16 enrolled

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07247786 2025-12-30

MIGRANT

68 enrolled

Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms

NCT05380713 2025-12-29

......SMARTEST Trial......

30 enrolled

Mesothelioma, Malignant

NCT04550104 2025-12-19

CONCORDE

Phase 1 Recruiting

200 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06680050 2025-12-18

AUSTRAL

21 enrolled

Non Small Cell Lung Cancer NSCLC

NCT04765709 2025-12-16

BRIDGE

Phase 2 Terminated

10 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05568212 2025-12-01

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

176 enrolled

Non-small-cell Lung Cancer Patients

NCT03999710 2025-11-28

Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer

61 enrolled

BreastDermatologicGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Recurrence

NCT02639026 2025-11-25

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

Phase 1 Completed

53 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms

NCT03916419 2025-11-12

Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer

26 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03581487 2025-11-05

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

Phase 1/2 Completed

40 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02572843 2025-10-28

Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)

68 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04397003 2025-10-22

Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer

6 enrolled

Small Cell Lung Carcinoma

NCT03237377 2025-10-14

Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer

Phase 2 Terminated

9 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT04108026 2025-10-03

SAVIMMUNE

50 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04472949 2025-10-01

Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).

46 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT05932199 2025-09-25

Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma

Phase 1/2 Recruiting

52 enrolled

Mesothelioma

NCT05856695 2025-09-24

TAXIO

67 enrolled

Small Cell Lung Cancer Extensive Stage

NCT04105270 2025-09-11

RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

82 enrolled

Adenocarcinoma of Lung, Lung Neoplasms

NCT05796089 2025-08-26

CHEST RT

35 enrolled

Small Cell Lung Carcinoma

NCT03620669 2025-08-15

1st Line Durvalumab in PS 2 NSCLC Patients

48 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04245514 2025-08-11

Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)

90 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03148327 2025-07-15

Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy

18 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04062708 2025-07-08

CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer

38 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04905316 2025-06-17

CHORUS

41 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05617963 2025-06-15

DURVALUNG

100 enrolled

Small Cell Lung Carcinoma

NCT05136846 2025-06-04

Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer

Phase 1 Recruiting

28 enrolled